Features

FDA approves Gilead's Zydelig for three types of blood cancers

Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has returned (relapsed). more »

Jul 24, 2014

Integra pIpette streamlines screening of novel protein therapeutics

Integrating an Integra VIAFLO 96 multichannel pipette into their high throughput expression facility has enabled Molecular Partners to streamline the discovery and development of a novel class of targeted protein therapeutics termed DARPins. more »

Jul 24, 2014 Lab Products

BMS and Ono Pharmaceutical announce strategic immuno-oncology collaboration in Japan, South Korea and Taiwan

As part of the agreement, BMS and Ono will jointly develop and commercialise Opdivo (nivolumab) and Yervoy (ipilimumab) across a broad range of tumour types. more »

Jul 24, 2014

Bavarian Nordic announces first patient treated in a phase I study of MVA-BN Brachyury in advanced cancer

This immunotherapy is designed to induce a robust immune response against Brachyury, a tumour-associated antigen which is overexpressed in every major solid tumour setting more »

Jul 24, 2014

FDA accepts Sandoz application for biosimilar filgrastim

The reference product is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant. more »

Jul 24, 2014

Implandata announces successful implantation of micro-sensor for intraocular pressure measurement in glaucoma patient

After implantation of the micro sensor the patient’s intraocular pressure measurements can be measured at any chosen frequency. more »

Jul 24, 2014

Medical Expo

Built with Metro Publisher™